X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
index medicus (15) 15
male (13) 13
middle aged (12) 12
female (11) 11
adult (10) 10
aged (9) 9
hepatitis (9) 9
cirrhosis (8) 8
liver (7) 7
patients (7) 7
abridged index medicus (6) 6
gastroenterology & hepatology (6) 6
hepatitis c virus (6) 6
hepatitis c, chronic - drug therapy (6) 6
liver cancer (6) 6
treatment outcome (6) 6
health aspects (5) 5
hepacivirus - genetics (5) 5
history (5) 5
infections (5) 5
internal medicine (5) 5
liver diseases (5) 5
medicine, general & internal (5) 5
ribavirin (5) 5
virus-infection (5) 5
analysis (4) 4
antiviral agents - administration & dosage (4) 4
antiviral agents - therapeutic use (4) 4
biological response modifiers (4) 4
drug therapy (4) 4
genotype (4) 4
hepacivirus - isolation & purification (4) 4
hepatitis b (4) 4
hepatitis c (4) 4
hepatitis c, chronic - complications (4) 4
hepatocellular carcinoma (4) 4
human immunodeficiency virus--hiv (4) 4
interferon (4) 4
life sciences (4) 4
ribavirin - administration & dosage (4) 4
rna, viral - blood (4) 4
therapy (4) 4
viral load (4) 4
virus diseases (4) 4
young adult (4) 4
abt-450/r-ombitasvir (3) 3
antiviral agents (3) 3
cancer (3) 3
care and treatment (3) 3
chronic infection (3) 3
combination (3) 3
digestive system diseases (3) 3
drug therapy, combination (3) 3
genotype & phenotype (3) 3
hepacivirus - classification (3) 3
hepatitis c, chronic - virology (3) 3
histoire (3) 3
hypertension (3) 3
imidazoles - administration & dosage (3) 3
infectious disease (3) 3
liver - pathology (3) 3
liver cirrhosis - virology (3) 3
medical colleges (3) 3
mortality (3) 3
multivariate analysis (3) 3
product development (3) 3
protease inhibitor (3) 3
protease inhibitors (3) 3
risk (3) 3
sofosbuvir (3) 3
survival (3) 3
sustained virological response (3) 3
1789-1945 (2) 2
17th century (2) 2
18th century (2) 2
[sdv.can]life sciences [q-bio]/cancer (2) 2
[sdv.mhep.heg]life sciences [q-bio]/human health and pathology/hépatology and gastroenterology (2) 2
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (2) 2
[sdv]life sciences [q-bio] (2) 2
adolescent (2) 2
alcoholic beverages (2) 2
allografts (2) 2
animals (2) 2
anrs co12 cirvir (2) 2
biopsy (2) 2
body mass index (2) 2
bouddhisme (2) 2
buddhism (2) 2
carcinoma, hepatocellular - drug therapy (2) 2
carcinoma, hepatocellular - mortality (2) 2
clinical trials (2) 2
cmec religion indiske religioner buddhisme (2) 2
dasabuvir (2) 2
diabetes mellitus (2) 2
diagnosis (2) 2
disease (2) 2
dna (2) 2
doctrines (2) 2
double-blind method (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Baycrest Hospital - Resident/Client Library (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University E.J. Pratt - Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 9, pp. 671 - 677
Journal Article
The Lancet, ISSN 0140-6736, 04/2019, Volume 393, Issue 10179, pp. 1453 - 1464
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, p. e37563
Background: Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated... 
SKELETAL-MUSCLE | CANCER-PATIENTS | MULTIDISCIPLINARY SCIENCES | VALIDATION | BODY-COMPOSITION | INHIBITOR | PHASE-I | Niacinamide - analogs & derivatives | Humans | Middle Aged | Liver Neoplasms - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Sarcopenia - chemically induced | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Liver Neoplasms - metabolism | Survival Analysis | Adult | Aged | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Carcinoma, Hepatocellular - metabolism | Pyridines - therapeutic use | Antimitotic agents | Medical research | Sarcopenia | Analysis | Diarrhea | Medicine, Experimental | Hepatoma | Antineoplastic agents | Liver cirrhosis | Nuclear magnetic resonance--NMR | Laboratories | Toxicity | Oncology | Hepatocellular carcinoma | Males | Body composition | Body mass index | Liver cancer | Angiogenesis | Toxicology | Computed tomography | Tomography | Nosocomial infections | Drug dosages | Teaching hospitals | Hypertension | Medical imaging | Pharmacology | Metabolism | Patients | Constraining | Feet | Musculoskeletal system | Clinical medicine | Pharmacokinetics | Tumors | Nuclear magnetic resonance | NMR
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 04/2018, Volume 67, Issue 4, pp. 1253 - 1260
Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited... 
VARIANTS | NS5A | GRAZOPREVIR | ELBASVIR | RESISTANCE | INFECTION | RETREATMENT | RIBAVIRIN | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | REGIMENS | Headache | Cirrhosis | Antiviral agents | Hepatitis | Liver diseases | Liver | Proteinase inhibitors | Interferon | Hepatitis C | Patients | Ribavirin | Genotypes | Original
Journal Article
Hepatology, ISSN 0270-9139, 10/2016, Volume 64, Issue 4, pp. 1136 - 1147
Journal Article